International Journal of Current Trends in Pharmaceutical Research

Journal Home Page: www.pharmaresearchlibrary.com/ijctpr

Research Article Open Access

Formulation and Comarative Evaluation of Amlodipine Besylate Fast Disintegrating Tabltes Prepared by Dry and Wet Granulation Techniques

B.V. Ramana[1]*, T.E.G.K. Murthy[2]

[1]*Research Scholar, Rayalaseema University, Kurnool, Andhra Pradesh, India*
[2]*Bapatla College of Pharmacy, Bapalta, Guntur Dist, A.P, India*

A B S T R A C T

An Attempt was made to improve the disintegration capacity and Dissolution efficiency of the prepared formulations with the use of mixture of superdisintegrants. Amlodipine Besylate prepared alone with super disintegrates has shown the less release profile when compared to the release profile shown by the formulations with mixture of super disintegrates. The work proved that though wet granulation technique is best suitable technique for the preparation of tablets, the tablets prepared by direct compression improved the rate of dissolution quietly which favored the objective of improved solubility and faster absorption. The basic approach followed by all the currently available technologies engaged in the formulation of Fast dissolving tablets is to maximize the porous structure of the tablet matrix and incorporate super disintegrating agents in optimum concentration so as to achieve rapid disintegration and instantaneous dissolution of the tablet along with good taste masking properties and excellent mechanical strength has been achieved. The availability of the various technologies and manifold advantages of Fast dissolving tablets will surely increase its popularity in the near future.

Keywords: Amlodipine besylate, Direct Compression, Wet Granulation, Disintegration

A R T I C L E I N F O

CONTENTS

Article History: Received 09 June 2016, **Accepted** 18 Aug 2016, **Available Online** 15 November 2016

***Corresponding Author**
B.V. Ramana
Research Scholar
Rayalaseema University,
Kurnool, Andhra Pradesh, India
Manuscript ID: IJCTPR3144

PAPER-QR CODE

Citation: B.V. Ramana. Formulation and Comarative Evaluation of Amlodipine Besylate Fast Disintegrating Tabltes Prepared by Dry and Wet Granulation Techniques. *Int. J. Curnt. Tren. Pharm, Res.*, 2016, 4(6): 314-321.

1. Introduction

Tablet is the most popular among all dosage forms existing today because of its convenience of self administration, compactness and easy manufacturing; however hand tremors, dysphasia in case of geriatric patients, the underdeveloped muscular and nervous systems in young individuals and h case of uncooperative patients, the problem of swallowing is common phenomenon which leads to poor patient compliance [1]. To overcome these drawbacks, mouth dissolving tablets (MDT) or orally disintegrating tablets; (ODT) has emerged as alternative oral dosage forms. These are novel types; of tablets that disintegrate/dissolve/ disperse in saliva within few seconds'. According to European Pharmacopoeia, the ODT should disperse/disintegrate in less than three minutes [2]. Amlodipine Besylate is a long-acting 1,4-dihydropyridine calcium channel blocker, Amlodipine Besylate belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. Amlodipine Besylate is slowly and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are reached 6-12 hour following oral administration. Its estimated bioavailability is 64-70%. Absorption is not affected by food. Its half life varies form 30-50 hours and having the pKa value of 11.03 shows that the drug is suitable candidate to formulate as fast disintegrating tablets 3.

2. Materials and Methods

Materials: Amlodipine Besylate was received as a gift sample from Aurobindo Pharmaceuiticals, Hyderabad. Croscarmellose Sodium, Crospovidone & Indion 414 were received as a gift sample from Hetero Pharma, Hyderabad. Pharmatose were received as a gift sample from Friesland food demo Ltd Mumbai. All other ingredients used were of research grade.

Methods:

Preformulation Studies [4]

Compatability studies: Interaction studies were conducted in between the Amlodipine Besylate and Superdisintegrants by I.R Spectral Studies.

Fourier Transform Infra Red Spectroscopy:

The Physico–Chemical Compatability between the Amlodipine Besylate and the Super disintegrants was carried out by using Perkin Elmer Fourier Transform Infra Red Spectrophotometer, Shelton USA. The sample scanned seperately under diffuse reflectance mold and plot of graph is given by taking the average of 100 scans. Before analysis the samples was completely dessicator dried.

Swelling study of super disintegrants:

The super disintegrants are studied for their swelling characters. For this study, a procedure given in the Indian Pharmacopoeia was used with little modification. 1g of the super disintegrant was transferred to a 100 ml measuring cylinder and water is taken up to 90 ml and shaken for 3 occasions during the period for 30 sec and allowed to stand for 15min avoiding entrapment of air. The volume was adjusted to 100ml with sufficient amount of water. The reading of the volume of the super disintegrants was noted. The swelling study was reported in the form of % swelling.

$$\text{Swelling studies (\%)} = \frac{\text{Final volume} - \text{Initial volume}}{\text{Initial Volume}} \times 100$$

Determination of Precompresion Characteristics

The following Preformulation studies were performed for Amlodipine Besylate formulations:

Angle of Repose: A funnel was fixed at a particular height on a burette stand. A graph paper was placed below the funnel on the table. The powdered drug passed through the funnel until it forms a pile. The radius of the pile was noted down. Angle of repose of the powder material was calculated using the formula.

$$\text{Angle of repose } \theta = \tan^{-1} H/r$$

Where, H is height of the pile, and r is radius of the pile.

Determination of Densities[5]:

Apparent Bulk Density:

The bulk density, as a measure used to describe packing materials or granules, was determined by transferring the accurately weighed amount of powder sample to the graduated cylinder with the aid of a funnel. The initial volume was noted. Ratio of weight of the sample to the volume it occupied was calculated.

Tapped Density:

Weighed powder sample was transferred to a graduated cylinder and was placed on the tapped density test apparatus, was operated for a fixed number of taps (100). The tapped density was determined as the ratio of weight of sample to tapped volume.

$$\text{Density} = \frac{\text{Mass}}{\text{Volume}}$$

Carr's Index (% Compressibility):

Based on the apparent bulk density and the tapped density, the percentage compressibility of the bulk drug was determined by using the following formula.

$$\text{\% compressibility} = \frac{\text{Tapped density} - \text{Bulk density}}{\text{Tapped density}}$$

Hausner's Ratio:

The ratio of tapped density to the bulk density of the powders is called the Hausner's ratio. Results are shown in Table 5.

Dispersibility [6]:

Weigh approximately about 1g of sample the material was droped from a total height (610mm) on to a tarred watch glass(dia-120mm) through a hallow cylinder placed vertically 102mm above the watch glass. The cylinder was secured to a support-stand by using support rings above and below the cylinder. The drop point is approximately 178mm vertically above the top of cylinder. The material lanned within the watch glass is weighed. Any loss of powder during the fall was the result of dispersion. The percent dispersibility was caluculated using the formula

$$\text{Dispersibility}(\%) = \frac{weight\,of\,power\,in\,watch\,glass}{initial\,weight\,of\,sample} \times 100$$

Porosity (€): Porosity of the compound is determined by liquid dispersion method [7]

$$(€) = \frac{bulkvolume - true\ volume}{bulk\ volume}$$

Formulation of Tablets [8]:

Direct Compression Method

The Tablets were prepared employing direct compression method. It is the process by which tablets are compressed directly from mixtures of the drug, super disintegrating agents and excipients without preliminary treatment such as granulation. All the formulations from F1 to F12 are prepared by direct Compression Technique reported in Table 1 and Table 2. The tablets were prepared by compression method using 7 mm biconcave punches on a 'EDISON mini press' a single station rotary compression mission.

Preparation of tablets by wet granulation method [9]:

Tablets containing 10 mg of Amlodipine Besylate were prepared by wet granulation method and the various formulae used in the study are shown in the table 3. The drug, diluent, are passed through sieve no 12. All the above ingredients were properly mixed together (in a poly-bag). Talc and magnesium oxide were passed through mesh number 80, mixed, and blended with initial mixture in a poly-bag followed by compression of the blend. The tablets were prepared by compression method using 7 mm bi concave punches on a 'EDISON mini press' a single station rotary compression mission

Evaluation Studies [10]

Hardness:

Pfizer hardness tester was used for the determination of the hardness of tablets. Tablet was placed in contact between the plungers, and the handle was pressed, the force of the fracture was recorded. Results are shown in Table 2.

Friability:

Two tablets were accurately weighed and placed in the friabilator (Electrolab. EF-2 Friabilator) and operated for 100 revolutions. The tablets were de-dusted and reweighed. The tablets that loose less than 1% weight were considered to be compliant.

Weight Variation:

10 tablets were selected randomly from the lot and weighed individually to check for weight variation.

Thickness and Diameter:

The thickness and diameter of 4 tablets were recorded during the process of compression using Vernier calipers.

Uniformity of dispersion:

2 tablets were placed in 100 ml water and stirred gently until completely dispersed. A smooth dispersion was obtained which passed through a sieve screen 710 m cm (sieve number 22).

Wetting time: A piece of tissue paper folded twice was placed in a small petridish (internal diameter = 6.5cm) containing 5 ml of distilled water. A tablet was placed on the paper, and the time for complete wetting of the tablet was measured in seconds

Disintegration test: Tablets were taken and introduced one tablet in each tube of disintegration apparatus, and the tablet rack of the disintegration apparatus was positioned into a 1-liter beaker and the time of disintegration was recorded. To discriminate between the formulations disintegration was done at room temperature and disk was not used for the study.

Drug Content [39]: Analytical methods for the estimation of Amlodipine Besylate:

Preparation of calibration curve:

100 mg of drug was accurately weighed and dissolved in 100ml of water and suitable dilution were made to get 2,4,6,8,10 µg/ml of the solution. Absorbance of various concentrations were measured by U.V spectrophotometer at 237 nm using buffer solution as blank. 10 tablets were weighed and powdered, powder equivalent to1 tablet (150mg) of Amlodipine Besylate was weighed and dissolved in pH 3 buffer and filtered the solution through the wattman filter paper. The filtrate was collected and diluted to a sufficient amount with pH 3 buffer till the conc. of the drug lies within the standard plot range. The diluted solution was analyzed for Amlodipine Besylate by UV-spectrophotometer (UV-ELICO SL 120).

Dissolution studies:

The in vitro dissolution study was carried out in the USP dissolution test apparatus (EDISON-[ESI-06] Dissolution tester USP) type 2 (paddle). 900 ml of the dissolution medium 0.1 N Hcl (P^H1.2) was taken in covered vessel and the temperature was maintained at 37 ± 0.5 ^{o} C. The speed of the paddle was set at 75 rpm. Sampling was done every one min interval. For each sample 5 ml of the dissolution medium was withdrawn and the same amount of dissolution medium at 37^{o}C was replenished to the dissolution medium. The % absorbance was determined.

3. Results and discussions



Figure 1: Construction of Calibration Curve



Figure 2: FTIR of Amlodipine Besylate



Figure 3: FTIR of CP-CSS



Figure 4: FTIR of SSG-CP



Figure 5: FTIR of SSG-CCS



Figure 6: FTIR of SSG + CCS +Amdp



Figure 7: FTIR of SSG + CP + Amdp



Figure 8: FTIR of CP + CSS +Amdp

Discussions

To study the interactions existing in between Amlodipine Besylate and the super disintegrants mixture were subjected to IR studies and the results were showed in Fig.2 to Fig.8. Table 4,5 and 6 shows the pre compression properties of powders and granules of which the angle of repose values of granules was less and it shows the better repose values compared to powders. All the formulations with the mixtures of Super Disintegrants in different ratios added in different methods shown the comfortable values no such longer deviations among the formulations. Angle of repose (lowest value 22.63 highest value 39.58) for powders and where as the value is comparatively less for granules (lower 22.53, higher (32.54) which proved the granules have better flow properties. Fast disintegrating tablets are prepared in a single-station rotary compression machine. Table 7 8 and 9 shows the post-compressional parameters, hardness (3.2-5.0 Kg/cm), friability (≤ 0.75 %), weight variation (Passes) values of the tablets. It indicates that with the change in method of tablet preparation and use of super disintegrants uniformity of dispersion test. The values also show that the usage of super disintegrants in combination showed faster disintegration in tablets rather than the tablets prepared without combination. But tablets prepared by direct compression method, showed satisfied results compared to wet method in combination of super disintegrants.

Disintegration time: The most important parameter that is needed to be optimized during the development of fast disintegrating tablets is disintegrating time of the tablets. The disintegration test of the tablets was conducted in

purified water. Disintegrating study showed that the disintegrating times (Table 7,8,9) of the tablets (from 31 to 72 sec) with various concentrations and mixture of super disintegrants (1:1). However, disintegration time of the tablets prepared with mixture of super disintegrants (1:1) are in the acceptable range with no much deviations due to combitional effect of super disintegrant mixture. The results are in consistent with other results. The mixture of disintegrants (6%) by prepared by direct compression method showed satisfactory results.

Wetting time:

Table 7,8 and 9 shows the wetting time data. The wetting times of tablets containing the mixture of super disintegrants (1:1) with various concentrations are in the acceptable range. Usually the crospovidone having the low swelling rate has also showed the fast wetting effect due to the combitional effect of super disintegrants. This is due to the Synergistic effect of the superdisintegrants taken as mixture in the ratio of 1:1.Increase in concentration of crosspovidone along with the other super disintegrants will modify the wetting property of crosspovidone and formulations prepared with the mixture of it. However, no significant change in the wetting time is seen with increase in the concentration of superdisintegrant mixture (1:1). The wetting time of the tablets prepared by wet granulation showed more time to get wet due to the solvation action, which proved anhydrates will have faster tendency for drug absorption.

***In-vitro* release studies:**

The dissolution of Amlodipine Besylate from the tablets is shown in figure 2, 3, 4 and 5 (Table 11&13) shows the T_{50}%andT_{90}% of the release profiles. T_{50}%andT_{90}% values varied with varying in the concentration and mixture of super dintegrants (1:1). However, T_{50}%andT_{90}% values are less for the formulations F10 and F12 comparing with marketed formulation and with the all other prepared. While T_{50}% and T_{90}% values did not change with increase in the concentration of crospovidone. The rapid increase in dissolution of Amlodipine Besylate in F10 and F12 may be due to rapid swelling of Crosscarmellose and sodium starch glycolate. The increase in the concentration of Crosscarmellose and sodium starch glycolate increased the swelling and disintegrating tablets rapidly into apparently primary particles. While tablets formulated with sodium starch glycolate, disintegrate by rapid uptake of water, followed by rapid and enormous swelling into primary particle but more fastly due to the change in viscous gel layer of sodium starch glycolate by crosspovidone.

Table 1: Tablets prepared by Direct Compression Method

Ingredients	F1	F2	F3	F4	F5	F6
Amlodipine (mgs)	10	10	10	10	10	10
Cc	6	-	-	9	-	-
Cp	-	6	-	-	9	-
Ssg	-	-	6	-	-	9
Lactose	35	35	35	35	35	35
Mcc	95	95	95	92	92	92
Talc	2	2	2	2	2	2
MgO	2	2	2	2	2	2

Table 2: Tablets prepared by Direct Compression Method using mixture of Super Disintegrants

Ingredients	F7	F8	F9	F10	F11	F12
Amlodipine (mgs)	10	10	10	10	10	10
Cc	3	3	-	4.5	4.5	-
Cp	3	-	3	4.5	-	4.5
Ssg	-	3	3	-	4.5	4.5
Lactose	35	35	35	35	35	35
Mcc	95	95	95	92	92	92
Talc	2	2	2	2	2	2
MgO	2	2	2	2	2	2

Note: CC, CP-4% -F1 (1:1) CC, SSG-4% -F2 (1:1) SSG, CP-4% -F3 (1:1)
CC, CP-6% -F4 (1:1) CC, SSG-6% -F5 (1:1) CC, SSG-6% -F5 (1:1)

Table 3: Tablets prepared by Wet Granulation Method using mixture of Super Disintegrants

Ingredients	F13	F14	F15	F16	F17	F18
Amlodipine (mgs)	10	10	10	10	10	10
Cc	3	3	-	4.5	4.5	-
Cp	3	-	3	4.5	-	4.5
Ssg	-	3	3	-	4.5	4.5
Lactose	35	35	35	35	35	35
Mcc	95	95	95	92	92	92
Talc	2	2	2	2	2	2
MgO	2	2	2	2	2	2

Table 4: Swelling studies of super disintegrants in purified water

Super disintegrant	**% Increase in volume**
Croscarmellose sodium	900
Sodium starch glycolate	650
Crospovidone	2.63

Table 5: Pre-compressional results of Formulations F1 to F6

Parameters	**F1**	**F2**	**F3**	**F4**	**F5**	**F6**
Angle of repose	32.23 ±0.026	39.68±0.33	37.92±0.192	32.21±0.01	35.59±0.519	36.69±1.407
Bulk density	0.79±0.0348	0.75±0.065	0.71±0.086	0.75±0.0084	0.72±0.0046	0.70±0.0076
Tapped Density (gm/cc)	0.56±0.67	0.65±0.22	0.69±0.11	0.55±0.23	0.65±0.28	0.58±0.45
Porosity	31 ±0.577	33.33±0.666	38±0.288	32.6±0.1414	34.3±0.2302	29.33±0.342
Carr's index	22.6±0.336	21.66±0.6645	23.33±0.333	29±0.318	19.16±0.118	25.33±0.331
Hausners Ratio	1.1±0.33	1.14±0.24	1.17±0.26	1.17±0.29	1.16±0.30	1.18±0.29
Dispersibility	80.6±0.13	92.53±0.24	88.53±0.28	84.83±0.27	92.3±0.34	93.6±0.32

Table 6: Pre-compressional results of Formulations F7 to F12

Parameters	**F7**	**F8**	**F9**	**F10**	**F11**	**F12**
Angle of repose	26.6±0.36	27.07±0.12	26.02±0.04	29.88±0.074	25.53±0.08	36.54±0.17
Bulk density	0.59±0.038	0.55±0.05	0.71±0.08	0.75±0.04	0.73±0.46	0.79±0.76
Tapped Density	0.53±0.37	0.37±0.42	0.31±0.31	0.44±0.33	0.71±0.38	0.28±0.24
Porosity	31±0.57	32.3±0.62	38±0.38	34.66±0.34	31.3±0.23	35.33±0.342
Carr's index	22.6±0.36	22.66±0.65	20.33±0.33	22±0.38	21.16±0.28	23.33±0.31
Dispersibility	79.6±0.06	74.53±0.17	79.53±0.59	72.83±0.07	85.3±0.33	84.6±0.23

Table 7: Pre-compressional results of Formulations F13 to F18

Parameter	**F13**	**F14**	**F15**	**F16**	**F17**	**F18**
Bulk density (gm/cc)	0.29±0.017	0.34±0.017	0.37±0.171	0.40±0.01	0.36±0.01	0.35±0.01
Tapped Density (gm/cc)	0.33±0.015	0.36±0.02	0.39±0.015	0.43±0.015	0.44±0.02	0.37±0.159
Porosity	16.2±0.346	24.2±0.152	24.17±0.026	24±1.529	25.2±0.152	18.2±0.173
Cars index	12.12±0.01	5.5±0.251	5.1±0.10	69±0.173	18.18±0.051	5.40±0.133
Hausners ratio	1.13±0.015	1.058±0.016	1.05±0.017	1.07±0.01	1.22±0.031	1.05±0.015
Dispersibility	80.5±0.586	65.3±0.21	68.2±0.305	54.2±0.212	65.2±0.173	70.2±0.32
Angle of repose(θ)	28.6±0.336	28.07±0.122	28.02±0.064	28.88±0.0574	22.53±0.058	30.54±0.167

Table 8: Post-compressional results of Formulations F1 to F6

Parameters	**F_1**	**F_2**	**F_3**	**F_4**	**F_5**	**F_6**
Hardness(kg/cm^2) (±SD), n=3	3.8±0.13	3.7±0.02	3.2±0.02	3.6±0.08	3.4±0.03	3.3±0.05
Friability (%) (±SD), n=3	0.87±0.5773	0.78±0.0411	0.85±0.0530	0.88±0.4966	0.95±0.5123	0.92±0.5211
Weight variation (mg) (±SD), n=20	Passes	Passes	Passes	Passes	Passes	Passes
Uniformity of Dispersion	Passes	Passes	Passes	Passes	Passes	Passes
Thickness (mm) (±SD), n=4	4.2± 0.05	4.1± 0.03	4.3± 0.23	4.2± 0.17	3.8± 0.21	4.14±0.43
Disintegration Time(sec)	98±0.12	97±1.26	90±1.4	65±2.3	78±2.2	72±1.8
Wetting Time (Sec)	50.3±0.36	53.3±0.16	55±0.15	54±0.25	42.6±0.54	49±0.33
Drug content (%)	96.5±0.22	97.6±0.42	98.9±0.18	99.2±0.76	97.1±0.75	98.5±0.29

Table 9: Post-compressional results of Formulations F7 to F12

Parameters	**F7**	**F8**	**F9**	**F10**	**F11**	**F12**
Hardness (kg/cm^2) (±SD), n=3	3.6±0.0443	4.8±0.0378	4.9±0.0223	5.0±0.0278	4.1±0.338	3.9±0.0511
Friability (%) (±SD), n=3	0.75±0.5773	0.69±0.0411	0.43±0.0530	0.21±0.4966	0.97±0.5123	0.14±0.5211
Weight variation (mg) (±SD), n=20	Passes	Passes	Passes	Passes	Passes	Passes
Uniformity of Dispersion	Passes	Passes	Passes	Passes	Passes	Passes

Thickness (mm) (±SD), n=4	4.28(0.05)	4.35(0.05)	4.33(0.05)	4.25(0.17)	4.32(0.18)	4.24(0.03)
Disintegration Time(sec) (±SD), n=6	22±0.22	18±0.32	19±0.57	11±1.5	15±0.18	19±0.22
Wetting Time (Sec) (±SD),n=6	32±0.336	28±0.346	32±0.397	27±0.399	30±0.397	24±0.344
Drug content (%) (±SD), n=6	99.5±0.52	99.6±0.62	98.9±0.58	100.2±0.68	98.9±0.57	101.0±0.81

Table 10: Post-compressional results of Formulations F13 to F18

	Wet Granulation					
Parameters	**F13**	**F14**	**F15**	**F16**	**F17**	**F18**
Hardness(kg/cm^2) (±SD), n=3	3.5±0.105	3.4±0.21	3.9±0.14	4.1±0.07	4.0±0.47	4.4±0.24
Friability (%) (±SD), n=3	0.91±0.204	0.93±0.54	0.89±0.47	0.92±0.054	0.95±0.402	0.72±0.71
Weight variation (mg)(±SD),n=20	Passes	Passes	Passes	Passes	Passes	Passes
Uniformity of Dispersion	Passes	Passes	Passes	Passes	Passes	Passes
Thickness (mm) (±SD), n=4	3.2±0.302	3.1±0.021	3.1±0.47	3.2±0.201	3.0±0.15	3.1±0.24
Disintegration Time (sec) (±SD), n=6	33±0.7	30±0.55	20±0.045	39±0.09	35±0.075	22±0.049
Wetting Time (Sec) (±SD), n=6	48±0.54	35±1.2	32±0.75	50±0.85	29±0.58	26±1.42S
Drug content (%) (±SD), n=6	98.5±1.2	99.5±0.7	99±0.65	98±0.84	98.7±0.102	98.5±0.6

Table 11A: Dissolution studies of Amlodipine Besylate by direct compression method & wet granulation method with different methods of super disintegrants addition (pH-1.2)

	Direct Compression					
Time intervals	**F7**	**F8**	**F9**	**F10**	**F11**	**F12**
5min	35.71±0.12	39.25±0.21	49.41±0.23	49.18±0.26	47.42±0.25	34.45±0.34
10min	48.53±0.31	51.64±0.14	60.32±0.33	58.79±0.33	56.32±0.26	47.25±0.42
15min	59.71±0.28	60.53±0.18	69.20±0.25	68.89±0.41	65.08±0.35	59.03±0.28
20min	68.10±0.29	66.34±0.22	80.16±0.28	78.70±0.16	73.91±0.36	66.64±0.26
25min	75.46±0.24	77.71±0.21	91.88±0.34	91.02±0.20	84.76±0.29	73.90±0.33
30min	91.38±0.19	86.49±0.36	97.67±0.31	94.48±0.13	90.72±0.24	90.24±0.31

Table 11B: Dissolution studies of Amlodipine Besylate by direct compression method & wet granulation method with different methods of super disintegrants addition (pH-1.2)

	Wet Granulation						
Time intervals	**F13**	**F14**	**F15**	**F16**	**F17**	**F18**	**Marketed Fmltn**
5min	58.33 ±0.24	48.46 ±0.32	50.34 ±0.28	44.84 ±0.204	36.34 ±0.17	48.22 ±0.21	62.30 ±0.14
10min	62.285 ±0.282	62.32 ±0.182	54.73 ±0.234	52.64 ±0.234	38.46 ±0.26	58.43 ±0.148	69.22 ±0.22
15min	68.06 ±0.132	64.66 ±0.14	57.93 ±0.182	58.24 ±0.182	36.49 ±0.21	68.93 ±0.23	71.28 ±0.12
20min	71.93 ±0.042	68.28 ±0.162	55.84 ±0.23	60.94 ±0.23	42.39 ±0.16	70.44 ±0.36	78.15 ±0.21
25min	76.66 ±0.132	71.0 ±0.156	65.86 ±0.24	66.86 ±0.24	46.34 ±0.023	82.46 ±0.042	83.33 ±0.30
30min	82.23 ±0.23	77.42 ±0.15	71.42 ±0.0216	68.42 ±0.0216	62.09 ±0.042	84.31 ±0.282	91.32 ±0.29

Table 12: Analysis of calibration curve data

S.No	**Conc.**	**Absorbance(nm)**
1	2	0.0759
2	4	0.1493
3	6	0.2409
4	8	0.325
5	10	0.419

Table 13A: Slope values & T_{50}, T_{90} values of Amlodipine Besylate

	Direct Compression					
Titles	F7	F8	F9	F10	F11	F12
Slope (k) Conc/min	3.32	2.04	3.89	2.84.	2.850	3.58
$T_{50(min)}$	11.218	9.03	8.238	9.75	12.15	13.60
$T_{90(min)}$	26.33	25.00	25.92	20.48	30.12	18.09

Table 13B: Slope values & T_{50}, T_{90} values of Amlodipine Besylate

	Wet Granulation						
Titles	F13	F14	F15	F16	F17	F18	Marketed Formltn
Slope (k) Conc/min	4.36	6.16	2.49	3.87	6.25	5.36	4.970
$T_{50(min)}$	4.143	13.72	4.43	8.82	28.79	8.55	3.96
$T_{90(min)}$	31.31	40.65	40.65	38.89	30.23	30.02	29.34

4. Conclusion

Fast dissolving tablets constitute an innovative dosage form, which overcomes the problem of swallowing and provides a quick onset of action. The paediatric and geriatric populations are the primary. Targets, as both the groups found it difficult to swallow conventional tablets. The basic approach followed by all the currently available technologies engaged in the formulation of Fast dissolving tablets is to maximize the porous structure of the tablet matrix and incorporate super disintegrating agents in optimum concentration so as to achieve rapid disintegration and instantaneous dissolution of the tablet along with good taste masking properties and excellent mechanical strength The availability of the various technologies and manifold advantages of Fast dissolving tablets will surely increase its popularity in the near future An Attempt was made to improve the disintegration capacity and Dissolution efficiency of the prepared formulations with the use of mixture of super disintegrants. Amlodipine Besylate prepared alone with super disintegrants has shown the less release profile when compared to the release profile shown by the formulations with mixture of super disintegrants. The introduction of fast dissolving dosage forms has solved some of the problems encountered in administration of drugs to the pediatric and elderly patient, which constitutes a large proportion of the world's population. Hence, patient demand and the availability of various technologies have increased the market share of Fast dissolving tablets, which in turn prolongs the patent life of a drug. Keeping in view of the advantages of the delivery system, rapidly disintegrating dosage forms have been successfully commercialized

5. References

[1] Habib, W., Khankari, R., Hontz, J., 2000, Fast-dissolving drug delivery systems, critical review in therapeutics, Drug Carrier Systems, 17(1):61-72.

[2] Chang, R., Guo, X., Burnside, B. A., Couch, R., 2000, Fast-dissolving tablets, Pharm. Tech., 24(6): 52-58.

[3] Mahesh D. Chavanpatil, Paras Jain, Sachin Chaudhari, Rajesh Shear and Pradeep R. Vavia Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin International Journal of Pharmaceutics Volume 316, Issues 1-2, 19 June 2006, Pages 86-92

[4] Dobetti, L., 2001, Fast-Melting Tablets: Developments and Technologies, Pharm. Tech., (Suppl.), 44-50.

[5] Kuchekar, B. S., Atul, Badhan, C., Mahajan, H. S., 2003, Mouth dissolving tablets: A novel drug delivery system, Pharma Times, 35, 7-9.

[6] Allen,L.V. and Wang, B., Particulate support matrix for making a rapidly dissolving tablet, 1997, US Patent 5595761.

[7] Dr.Avani F. Amin Emerging Trends In The Development Of Orally Disintegrating Tablet Technology pharmainfo.net 01/26/2006

[8] Kumaresan C, Orally Disintegrating Tablet - Rapid Disintegration, Sweet Taste, And Target Release Profile, sep 9 2008, pharmainfo.net

[9] Kuchekar, B. S., Atul, Badhan, C., Mahajan, H. S., 2003, Mouth dissolving tablets: A novel drug delivery system, Pharma Times, 35, 7-9. \

[10] Allen,L.V. and Wang, B., Particulate support matrix for making a rapidly dissolving tablet, 1997, US Patent 5595761.

[11] Bradoo, R., Fast Dissolving Drug Delivery Systems, JAMA India, 2001, 4 (10), 27-31.

[12] .http://www.pharmpedia.com/Tablet: formulation of tablet disintegrants.

[13] .http://www.nbent.com/crosscarmellose.htm

[14] http://www.fmcbiopolymer.com/pharmaceutical/Products/AcDiSol/tabid/2921/Default.aspx

[15] http://www.generichem.com/avebe/Primellose.htm